Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127556141 | 12755614 | 1 | I | 20160309 | 20160906 | 20160916 | 20160916 | EXP | JP-MALLINCKRODT-T201604396 | MALLINCKRODT | 57.00 | YR | M | Y | 47.00000 | KG | 20160916 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127556141 | 12755614 | 1 | PS | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 5 MG (15 MG DAILY DOSE) | UNKNOWN | 40517 | TABLET | ||||||||
| 127556141 | 12755614 | 2 | SS | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 10 MG (20 MG DAILY DOSE) | UNKNOWN | 40517 | TABLET | ||||||||
| 127556141 | 12755614 | 3 | SS | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 10 MG (30 MG DAILY DOSE) | UNKNOWN | 40517 | TABLET | ||||||||
| 127556141 | 12755614 | 4 | SS | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 20 MG (40 MG DAILY DOSE) | UNKNOWN | 40517 | TABLET | ||||||||
| 127556141 | 12755614 | 5 | SS | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 20 MG (60 MG DAILY DOSE) | UNKNOWN | 40517 | TABLET | ||||||||
| 127556141 | 12755614 | 6 | SS | METHADONE | METHADONE HYDROCHLORIDE | 1 | Oral | 20 MG (80 MG DAILY DOSE) | UNKNOWN | 40517 | TABLET | ||||||||
| 127556141 | 12755614 | 7 | C | OXINORM | OXYCODONE HYDROCHLORIDE | 1 | Oral | 10 MG, PRN | 0 | 10 | MG | ||||||||
| 127556141 | 12755614 | 8 | C | DECADRON | DEXAMETHASONE | 1 | Oral | 4 MG | 0 | ||||||||||
| 127556141 | 12755614 | 9 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 15 MG | 0 | ||||||||||
| 127556141 | 12755614 | 10 | C | URIEF | SILODOSIN | 1 | Oral | 15 MG | 0 | ||||||||||
| 127556141 | 12755614 | 11 | C | NAIXAN | NAPROXEN SODIUM | 1 | Oral | 300 MG | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127556141 | 12755614 | 1 | Cancer pain |
| 127556141 | 12755614 | 7 | Analgesic therapy |
| 127556141 | 12755614 | 11 | Analgesic therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127556141 | 12755614 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127556141 | 12755614 | Prostate cancer |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127556141 | 12755614 | 1 | 20151201 | 20151207 | 0 | |
| 127556141 | 12755614 | 2 | 20151208 | 20151220 | 0 | |
| 127556141 | 12755614 | 3 | 20151221 | 20151227 | 0 | |
| 127556141 | 12755614 | 4 | 20151228 | 20160222 | 0 | |
| 127556141 | 12755614 | 5 | 20160223 | 20160306 | 0 | |
| 127556141 | 12755614 | 6 | 20160307 | 20160309 | 0 | |
| 127556141 | 12755614 | 7 | 20151203 | 0 | ||
| 127556141 | 12755614 | 11 | 20151201 | 0 |